Press release from Companies
Published: 2024-10-10 08:30:00
A new publication demonstrates how XposeALI®, Inhalation Sciences’ in vitro cell-based exposure module, successfully predicted the toxicity of inhaled palladium nanoparticles, an emerging pollutant from motor vehicles, in the lung lining. The study was carried out, and the paper co-authored, by scientists from Karolinska Institutet and the Swedish University of Agricultural Sciences as well as Inhalation Sciences. The paper is published in Frontiers in Medicine (Pulmonary Medicine section).
Palladium nanoparticle (Pd-NP) emissions from catalytic converters are emerging as a potential serious health risk. But how exactly might they behave in the lung lining of chronic and nonchronic bronchitis patients, and how can this be modelled accurately in an in vitro setting?
In this collaborative research project XposeALI® was used to predict the toxic potential of Pd-NP using cell-line models of normal and chronic bronchitis-like mucosa cells. The study found that XposeALI® closely mimicked in vivo lung environments and cell-particle interactions, maximizing the reliability of in vitro findings in human health toxicology risk assessments.
The publication is titled Cell line-based in vitro models of normal and chronic bronchitis-like airway mucosa to study the toxic potential of aerosolized palladium nanoparticles.
ISAB CEO Manoush Masarrat: "We were very happy to collaborate with our colleagues at KI. This project demonstrates again how XposeALI® can generate precise data on the cellular effects of inhaled particles in the lung lining using minimal amounts of test substance and reducing the amount of animal testing needed".
Read more about XposeALI® here.
Explore ISAB’s publications here.
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled
